Through our integration with Mayo Clinic, Mayo Clinic Laboratories leads the industry in turning test results into clinical answers. Mayo Clinic Laboratories’ comprehensive test menu has been created to aid in screening, diagnosis, and treatment selection across the full spectrum of hematologic disorders. Through our clinical experience, we have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Highlights
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Ewa Wysokinska, M.D., an assistant professor of medicine and consultant in the division of hematology and oncology at Mayo Clinic in Florida, to talk about clinical updates in thrombotic thrombocytopenic purpura.
Register now – Sept. 12, 2024: In this “Future Direction of Laboratory Medicine” webinar, Maggie DiGuardo, M.D., and Justin Juskewitch, M.D., Ph.D., will review the current knowledge regarding sickle cell disease from its genetic cause to the myriads of effects it can have for affected individuals.
Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.
Presented by Mayo Clinic Laboratories, the Classical Hematology Conference, happening Oct. 15–17, is an essential event for professionals in hematology, including medical practitioners, researchers, and laboratory specialists.
Join us for the Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, presented by Mayo Clinic Laboratories. This hybrid conference held Oct. 15–17, 2024, in Scottsdale, Arizona, will provide reviews and updates about the laboratory and clinical aspects of nonmalignant hematology and bleeding and thrombotic disorders.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
On the brink of losing her battle with acute myeloid leukemia, Shannon Camlek arrived at Mayo Clinic as a last hope. Her chances didn’t look good, but with the help of specialized genetic testing, particularly FISH (fluorescence in situ hybridization) studies, doctors were able to detect the specific gene mutations responsible for her symptoms and disease. The test results also helped Shannon’s care team target her treatment accordingly, and finally put an end to what Shannon likens as starring in her own personal horror movie while in search of hope and healing.
One summer morning, James Kypuros awoke to find his toes stiffened like claws. Then he started having falls, which culminated in losing his ability to walk or even sit up without help. Diagnosed with stiff-person syndrome, James wouldn’t find hope or relief until he was treated for glycine receptor antibody syndrome following specialized testing by Mayo Clinic.
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.